I oversee a team that delivers reimbursement strategy and health policy consulting for pharmaceutical, biotechnology, and medical device clients. My team and I analyze the environment to provide strategic guidance on how to best navigate today’s most pressing coverage and access challenges.
I am a recognized subject matter expert on the Affordable Care Act, quality measures, medication adherence and federal health programs — particularly the Medicare Prescription Drug Benefit (Part D) — and have presented nationally for health plans, payer, patient, and pharmaceutical audiences.
My experience in reimbursement and policy extends across multiple therapeutic areas, including cardiovascular, respiratory, mental health, diabetes, oncology, and inflammation. I have also acted as the director of policy and executive branch advocacy for a large pharmaceutical manufacturer and represented the organization through a variety of trade associations, including PhRMA, BIO, and the National Pharmaceutical Council.
In addition, I worked at the CMS in the Office of Exchanges developing policies on essential health benefits, oversight, essential community providers, and basic health plans. I have also held a position as a senior benefits analyst at Stanford University where I implemented both a consumer-driven health plan and a pharmacy benefit manager program.
I received my Master of Public Health from the University of North Carolina-Chapel Hill and a Bachelor of Science in Russian from Georgetown University.